Clinical Trial Update: Cabozantinib in Men With Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating cabozantinib in men with castration-resistant prostate cancer has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Washington | Conditions: Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-12-04